Page last updated: 2024-11-11

oudemansin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oudemansin: strong antifungal properties & inhibits respiration in fungi, cells of ascitic form of EHRLICH carcinoma & rat liver mitochondria; structure; biological activity depends on methoxyacrylate moiety [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438712
CHEMBL ID1094279
CHEBI ID174767
MeSH IDM0080489

Synonyms (17)

Synonym
oudemansin
(-)-oudemansin a
CHEMBL1094279
methyl (e,2e,3s,4s)-4-methoxy-2-(methoxymethylidene)-3-methyl-6-phenylhex-5-enoate
5-hexenoic acid, 4-methoxy-2-(methoxymethylene)-3-methyl-6-phenyl-, methyl ester, (2e,3r*,4r*,5e)-(-)-
oudemansin b
73341-71-6
5-hexenoic acid, 4-methoxy-2-(methoxymethylene)-3-methyl-6-phenyl-, methyl ester, (s-(r*,r*-(e,e)))-
af4t7p745y ,
unii-af4t7p745y
oudemansin a
(-)-odemasin a
Q16979497
CHEBI:174767
oudemansin a, (-)-
5-hexenoic acid, 4-methoxy-2-(methoxymethylene)-3-methyl-6-phenyl-, methyl ester, (2e,3s,4s,5e)-
DTXSID401031462
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
styrenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID477972Cytotoxicity against human MCF7 cells by resazurin microplate assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID477970Antifungal activity against Candida albicans2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID477973Cytotoxicity against human NCI-H187 cells by resazurin microplate assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID477974Cytotoxicity against african green monkey Vero cells by green fluorescent protein assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID477975Antimalarial activity against Plasmodium falciparum K12010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
AID477971Cytotoxicity against human KB cells by resazurin microplate assay2010Journal of natural products, Apr-23, Volume: 73, Issue:4
Bioactive metabolites from cultures of basidiomycete Favolaschia tonkinensis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (25.00)18.7374
1990's4 (33.33)18.2507
2000's1 (8.33)29.6817
2010's2 (16.67)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.08 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]